Senior Director, Team Lead, CDK4/6 Portfolio, US Breast Cancer
Pfizer - 2 Locations
Posted Nov 16, 2026
Benefits
- Parental leave
- 12 weeks From the posting source
- Non-birth-parent leave
- 12 weeks From the posting source
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Source-linked checked May 7, 2026
- Salary
- $231K-$385K From the posting source
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Role
- Seniority
- Staff Plus From the posting source
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
- Equity
- Offered Verified - SEC 10-K source
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Senior Director, Team Lead, CDK4/6 Portfolio, US Breast Cancer 2 Locations ROLE SUMMARY Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting-edge science into market-shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI-enabled infrastructure and the authority to accelerate medicines from discovery to delivery. Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you-across teams, roles, and the Pfizer enterprise. Join us to make history - for patients, for their families, for the future. Breast cancer is the most common cancer affecting women in the US, and IBRANCE, our first-in-class CDK 4/6 inhibitor, has been prescribed to ~200,000 patients in the US since launch. In 2026, IBRANCE contributed >$2B in net revenue to Pfizer Oncology and continues to be a market leader despite intensifying competition. With the June 2026 FDA approval of the PATINA HER2+ indication, IBRANCE is now the only CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status. The next three years are the most consequential in the history of Pfizer's breast cancer business. IBRANCE faces IRA effectuation and LOE in 2027, and atirmociclib, our CDK4-selective inhibitor, is the portfolio's planned successor. Phase 2 randomized results from the
Read the full description at pfizer.wd1.myworkdayjobs.com. FewerJobs shows a preview and links to the original posting.
Apply link verified; last checked Nov 20, 2026.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
Senior Director, Team Lead, KAT6i (Prifetrastat), US Breast Cancer
Pfizer - 2 Locations
Senior Director Oncology Commercial Strategy Biomarkers
Bristol Myers Squibb - Princeton - NJ - US
Senior Director, Global Market Access
Cogent Biosciences Inc - Waltham, Massachusetts, United States
Director - Strategic Collaborations (POA)
Caris Life Sciences - 2 Locations